Jupiter Topco LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,039,763 shares of the life sciences company’s stock, valued at approximately $358,652,000. Jupiter Topco LLC owned about 1.35% of Illumina as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of the business. Empowered Funds LLC raised its position in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina during the second quarter worth approximately $621,000. CW Advisors LLC bought a new stake in shares of Illumina in the second quarter worth $275,000. Marshall Wace LLP raised its holdings in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC boosted its stake in Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Royal Bank Of Canada lifted their target price on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $188.40.
Illumina Stock Up 0.8%
NASDAQ:ILMN opened at $224.99 on Wednesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a 50 day moving average of $190.35 and a 200-day moving average of $153.78. The firm has a market capitalization of $33.97 billion, a PE ratio of 41.98, a price-to-earnings-growth ratio of 3.14 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $226.84.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.
Insider Buying and Selling
In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the transaction, the director owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. This represents a 17.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,095,958 shares of company stock valued at $401,720,974. 2.90% of the stock is owned by corporate insiders.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
- Five stocks we like better than Illumina
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
